44O - CCTG IND.231: A phase 1 trial evaluating CX-5461 in Patients with Advanced Solid Tumors

Date 06 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Proffered Paper Session 2
Topics Cytotoxic agents
Presenter John Hilton
Citation Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048
Authors J. Hilton1, D.W. Cescon2, P. Bedard3, H. Ritter4, D. Tu4, J. Soong5, K. Gelmon6, S. Aparicio7, L. Seymour8
  • 1Medical Oncology, Ottawa Hospital Cancer Centre, K1H 8L6 - Ottawa/CA
  • 2Medical Oncology, Princess Margaret Hospital, Toronto/CA
  • 3Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 4Canadian Cancer Trials Group, Kingston/CA
  • 5Senhwa Biosciences, New Taipei City/TW
  • 6British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 7Department Of Pathology And Laboratory Medicine, University of British Columbia, V5Z 1L3 - Vancouver/CA
  • 8Canadian Cancer Trials Group, K7L 3N6 - Kingston/CA


G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions that can lead to replication fork collapse and double-stranded DNA breaks. Preclinical work by our group has demonstrated that CX-5461 can stabilize G-quadruplexes, resulting in synthetic lethality in BRCA1/2 deficient cell lines and xenograft models.